|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar V, Mitchell RS, Abbas AK and Fausto
N: The female genital system and breast. Robbins Basic Pathology
(8th). Saunders Elsevier. (Philadelphia, PA). 345–355. 2007.
|
|
3
|
Canavan TP and Doshi NR: Cervical cancer.
Am Fam Physician. 61:1369–1376. 2000.PubMed/NCBI
|
|
4
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berman ML, Keys H, Creasman W, DiSaia P,
Bundy B and Blessing J: Survival and patterns of recurrence in
cervical cancer metastatic to periaortic lymph nodes (a Gynecologic
Oncology Group study). Gynecol Oncol. 19:8–16. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Piver MS, Barlow JJ and Krishnamsetty R:
Five-year survival (with no evidence of disease) in patients with
biopsy-confirmed aortic node metastasis from cervical carcinoma. Am
J Obstet Gynecol. 139:575–578. 1981.PubMed/NCBI
|
|
7
|
Varia MA, Bundy BN, Deppe G, Mannel R,
Averette HE, Rose PG and Connelly P: Cervical carcinoma metastatic
to para-aortic nodes: Extended field radiation therapy with
concomitant 5-fluorouracil and cisplatin chemotherapy: A
Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys.
42:1015–1023. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim YS, Kim JH, Ahn SD, Lee SW, Shin SS,
Nam JH, Kim YT, Kim YM, Kim JH and Choi EK: High-dose
extended-field irradiation and high-dose-rate brachytherapy with
concurrent chemotherapy for cervical cancer with positive
para-aortic lymph nodes. Int J Radiat Oncol Biol Phys.
74:1522–1528. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grigsby PW, Heydon K, Mutch DG, Kim RY and
Eifel P: Long-term follow-up of RTOG 92-10: Cervical cancer with
positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys.
51:982–987. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Small W Jr, Winter K, Levenback C, Iyer R,
Gaffney D, Asbell S, Erickson B, Jhingran A and Greven K:
Extended-field irradiation and intracavitary brachytherapy combined
with cisplatin chemotherapy for cervical cancer with positive
para-aortic or high common iliac lymph nodes: Results of ARM 1 of
RTOG 0116. Int J Radiat Oncol Biol Phys. 68:1081–1087. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nugent EK, Case AS, Hoff JT, Zighelboim I,
DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS and Rader
JS: Chemoradiation in locally advanced cervical carcinoma: An
analysis of cisplatin dosing and other clinical prognostic factors.
Gynecol Oncol. 116:438–441. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carballo N, González-Cortijo L,
González-Martin A, Rojo A and Chiva L: Indications for adjuvant
radiotherapy treatment after surgery and novel modalities for
treatment. Gynecol Oncol. 110(Suppl 2): S41–S44. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Desoize B and Madoulet C: Particular
aspects of platinum compounds used at present in cancer treatment.
Crit Rev Oncol Hematol. 42:317–325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pecorelli S, Zigliani L and Odicino F:
Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol
Obstet. 105:107–108. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lim K, Small W Jr, Portelance L,
Creutzberg C, Jürgenliemk-Schulz IM, Mundt A, Mell LK, Mayr N,
Viswanathan A, Jhingran A, et al: Consensus guidelines for
delineation of clinical target volume for intensity-modulated
pelvic radiotherapy for the definitive treatment of cervix cancer.
Int J Radiat Oncol Biol Phys. 79:348–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Small W Jr, Mell LK, Anderson P,
Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L,
Schefter T, Iyer R, et al: Consensus guidelines for delineation of
clinical target volume for intensity-modulated pelvic radiotherapy
in postoperative treatment of endometrial and cervical cancer. Int
J Radiat Oncol Biol Phys. 71:428–434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cancer Therapy Evaluation Program: Common
Terminology Criteria for Adverse Events. Version 3.0. simplectep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf#searchAccessed.
December 20–2008
|
|
18
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Portelance L, Chao KS, Grigsby PW, Bennet
H and Low D: Intensity-modulated radiation therapy (IMRT) reduces
small bowel, rectum, and bladder doses in patients with cervical
cancer receiving pelvic and para-aortic irradiation. Int J Radiat
Oncol Biol Phys. 51:261–266. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gerszten K, Colonello K, Heron DE, Lalonde
RJ, Fitian ID, Comerci JT, Selvaraj RN and Varlotto JM: Feasibility
of concurrent cisplatin and extended field radiation therapy (EFRT)
using intensity-modulated radiotherapy (IMRT) for carcinoma of the
cervix. Gynecol Oncol. 102:182–188. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salama JK, Mundt AJ, Roeske J and Mehta N:
Preliminary outcome and toxicity report of extended-field,
intensity-modulated radiation therapy for gynecologic malignancies.
Int J Radiat Oncol Biol Phys. 65:1170–1176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jensen LG, Hasselle MD, Rose BS, Nath SK,
Hasan Y, Scanderbeg DJ, Yashar CM, Mundt AJ and Mell LK: Outcomes
for patients with cervical cancer treated with extended-field
intensity-modulated radiation therapy and concurrent cisplatin. Int
J Gynecol Cancer. 23:119–125. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kodama J, Takemoto M, Seki N, Nakamura K,
Hongo A, Kanazawa S and Hiramatsu Y: Phase I study of weekly
nedaplatin and concurrent pelvic radiotherapy as adjuvant therapy
after radical surgery for cervical cancer. Int J Gynecol Cancer.
18:1037–1041. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Niibe Y, Tsunoda S, Jobo T, Imai M, Matsuo
K, Matsunaga K, Unno N and Hayakawa K: Phase II study of radiation
therapy combined with weekly nedaplatin in locally advanced uterine
cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology
Group (KGROG 0501)-initial analysis. Eur J Gynaecol Oncol.
29:222–224. 2008.PubMed/NCBI
|
|
25
|
Walker JL, Morrison A, DiSilvestro P and
von Gruenigen VE: Gynecologic Oncology Group: A phase I/II study of
extended field radiation therapy with concomitant paclitaxel and
cisplatin chemotherapy in patients with cervical carcinoma
metastatic to the para-aortic lymph nodes: A Gynecologic Oncology
Group study. Gynecol Oncol. 112:78–84. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eifel PJ, Winter K, Morris M, Levenback C,
Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic
irradiation with concurrent chemotherapy versus pelvic and
para-aortic irradiation for high-risk cervical cancer: An update of
radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol.
22:872–880. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sood BM, Gorla GR, Garg M, Anderson PS,
Fields AL, Runowicz CD, Goldberg GL and Vikram B: Extended-field
radiotherapy and high-dose-rate brachytherapy in carcinoma of the
uterine cervix: Clinical experience with and without concomitant
chemotherapy. Cancer. 97:1781–1788. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ring KL, Young JL, Dunlap NE, Andersen WA
and Schneider BF: Extended-field radiation therapy with whole
pelvis radiotherapy and cisplatin chemosensitization in the
treatment of IB2-IIIB cervical carcinoma: A retrospective review.
Am J Obstet Gynecol. 201:109.e1–e6. 2009. View Article : Google Scholar
|
|
29
|
Uno T, Mitsuhashi A, Isobe K, Yamamoto S,
Kawakami H, Ueno N, Usui H, Tate S, Kawata T and Ito H: Concurrent
daily cisplatin and extended-field radiation therapy for carcinoma
of the cervix. Int J Gynecol Cancer. 18:80–84. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chung YL, Jian JJ, Cheng SH, Hsieh CI, Tan
TD, Chang HJ, Hung CF, Horng CF, Soong T and Tsou MH:
Extended-field radiotherapy and high-dose-rate brachytherapy with
concurrent and adjuvant cisplatin-based chemotherapy for locally
advanced cervical cancer: A phase I/II study. Gynecol Oncol.
97:126–135. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Malfetano JH, Keys H, Cunningham MJ,
Gibbons S and Ambros R: Extended field radiation and cisplatin for
stage IIB and IIIB cervical carcinoma. Gynecol Oncol. 67:203–207.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ahmed RS, Kim RY, Duan J, Meleth S, De Los
Santos JF and Fiveash JB: IMRT dose escalation for positive
para-aortic lymph nodes in patients with locally advanced cervical
cancer while reducing dose to bone marrow and other organs at risk.
Int J Radiat Oncol Biol Phys. 60:505–512. 2004. View Article : Google Scholar : PubMed/NCBI
|
